Synergy Pharmaceuticals Director Gabriel Cerrone Buys 12,000 Shares (SGYP)
Synergy Pharmaceuticals (NASDAQ:SGYP) Director Gabriel Cerrone bought 12,000 shares of Synergy Pharmaceuticals stock in a transaction that occurred on Tuesday, October 29th. The shares were purchased at an average cost of $4.09 per share, for a total transaction of $49,080.00. Following the transaction, the director now directly owns 187,470 shares of the company’s stock, valued at approximately $766,752. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Separately, analysts at Cantor Fitzgerald cut their price target on shares of Synergy Pharmaceuticals from $15.00 to $11.00 in a research note to investors on Monday, August 12th. They now have a “buy” rating on the stock. Five research analysts have rated the stock with a buy rating, Synergy Pharmaceuticals currently has an average rating of “Buy” and an average price target of $14.67.
Shares of Synergy Pharmaceuticals (NASDAQ:SGYP) traded up 3.48% during mid-day trading on Tuesday, hitting $4.16. 591,046 shares of the company’s stock traded hands. Synergy Pharmaceuticals has a 52 week low of $2.98 and a 52 week high of $7.44. The stock’s 50-day moving average is $4.55 and its 200-day moving average is $4.99. The company’s market cap is $375.2 million.
Synergy Pharmaceuticals, Inc is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (NASDAQ:SGYP), disorders and diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.